News and Trends 21 Dec 2017 Scientists Find New Immune Target to Stop Progression of Alzheimer’s Scientists have described a new mechanism by which the immune system can drive Alzheimer’s and shown that blocking it can prevent the disease in mice. A study published yesterday in Nature details how a molecule involved in the innate immune response can promote the aggregation of amyloid-β plaques that appear in the brains of patients […] December 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2017 Finnish Scientists Find Brain Cells Involved in Alzheimer’s Disease Alzheimer’s disease is rapidly increasing in prevalence but we have no effective treatment. But, Finnish Researchers have found a new target to investigate. Researchers at the University of East Finland have found that astrocytes, the cells that support the brain, could play a major role in the pathogenesis of Alzheimer’s disease. The research, published in […] November 22, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2017 German Diagnostics Firm Tackles Early Detection of Cancer, Alzheimer’s and Parkinson’s Hummingbird Diagnostics has teamed up with Saarland University to develop molecular diagnostics that can detect serious diseases early using blood samples. Based in Heidelberg, Germany, Hummingbird Diagnostics develops early diagnostics in multiple disease areas, ranging from cancer to cardiovascular and neurodegenerative disease. Its technology is based in the detection of miRNA, molecules that are involved […] November 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2017 Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II AC Immune’s Anti-Tau antibody for the treatment of Alzheimer’s disease has reached Phase II, prompting milestone payments from Genentech. Today, the first patient in a Phase II trial was dosed with AC Immune’s anti-Tau antibody for the treatment of Alzheimer’s disease. This triggered a milestone payment of CHF 14M (€12M) from its collaborator, Genentech, as part of an agreement […] November 2, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 German Drug to Stop the Progression of Alzheimer’s Enters Phase IIb Probiodrug is ready to start a Phase IIb trial with an Alzheimer’s drug that prevents the formation of Aβ plaques before the disease progresses. The German biotech Probiodrug is getting ready to start two Phase II trials to study the safety and efficacy of its candidate PQ912, a drug designed to intervene in the early stages of […] October 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 19 Sep 2017 Scottish Scientists Claim that the Genome Controls the Aging of the Brain Scientists in Scotland claim gene expression in the brain is so precisely controlled that they could predict your age just by looking at your genome. Researchers at the University of Edinburgh believe that genes in the brain are expressed at very specific times during a person’s life to carry out particular functions. Changes were seen […] September 19, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2017 Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal Allergan’s partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer’s disease. A year ago, Allergan signed a massive deal of up to €3Bn with Heptares Therapeutics for the development of drugs that target G-protein-coupled receptors (GPCRs), a protein superfamily that currently comprises the target of around […] September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2017 German Scientists Publish New Mechanism of Action Against Alzheimer’s Researchers at the German biotech Probiodrug have published today the detailed mechanism of action of a drug that might succeed in treating Alzheimer’s where many others have failed. Probiodrug is developing a therapeutic antibody with a unique mode of action against Alzheimer’s, PBD-C06. The company announced yesterday the publication in the Journal of Biological Chemistry of the detailed binding […] August 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2017 FREE White Paper! All You need to Know about Omics and Body Fat What do you think when you hear the word ‘lipid’? I bet your thoughts include fat, energy, hormones, maybe cells? But what if I told you that lipids can also be considered as biomarkers? Very important biomarkers too that can be analyzed and identified using multiparametric statistical analysis! With more and more research focusing on […] July 19, 2017 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2017 Cutting Through the BS in Biopharma: How To Spot Hype Faced with the oft-quoted figure that 90% of clinical trials end in failure, how can patients, investors, and readers be spared more disappointment? After discussing failures in biotech at Refresh earlier in June, I headed to Copenhagen last week for the European Conference for Science Journalists to cajole a panel into discussing how some of these stories feature […] July 5, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2017 A Spanish Vaccine to fight Alzheimer’s Before Symptoms Appear enters Phase II Araclon Biotech will advance to Phase II with an Alzheimer’s vaccine that could succeed where many others have failed before. Araclon Biotech, in Zaragoza, Spain, has announced today the approval from the Spanish Agency of Medicines and Medical Devices to start a Phase II trial testing its Alzheimer’s vaccine in 120 patients in 22 centers across Europe. The […] June 27, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jun 2017 Videos: Who won the Refresh Early-Stage Startup Battle? The Bonsai goes to… As you might have read in our recap, we had not one but two startup battles for the last edition of Refresh. Watch the companies’ pitches below! Up first was Cambridge Cancer Genomics, which uses AI to design personalised DNA-based tests to help clinicians to better track their patients’ responses to cancer drugs in order to make […] June 26, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email